What’s Ahead for Aptevo Therapeutics Inc (NASDAQ:APVO) After Less Shorted Shares?

June 18, 2018 - By Vivian Currie

The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) registered a decrease of 18.52% in short interest. APVO’s total short interest was 197,500 shares in June as published by FINRA. Its down 18.52% from 242,400 shares, reported previously. With 155,500 shares average volume, it will take short sellers 1 days to cover their APVO’s short positions. The short interest to Aptevo Therapeutics Inc’s float is 1.29%.

The stock increased 1.82% or $0.09 during the last trading session, reaching $5.03. About 26,113 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has risen 156.13% since June 18, 2017 and is uptrending. It has outperformed by 143.56% the S&P500.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $113.61 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 35.42 P/E ratio. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Another recent and important Aptevo Therapeutics Inc. (NASDAQ:APVO) news was published by Nasdaq.com which published an article titled: “Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10” on May 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: